Roy Mitchel Fleischmann MD
Clinical Professor of Medicine, University Tex SW Dallas
Join to View Full Profile
8144 Walnut Hill LnSuite 800Dallas, TX 75231
Phone+1 214-540-0700
Fax+1 214-540-0701
Dr. Fleischmann is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Board certified rheumatologist
Education & Training
New York Presbyterian Hospital (Columbia Campus)Fellowship, Rheumatology, 1973 - 1974
Icahn School of Medicine at Mount Sinai/Mount Sinai HospitalResidency, Internal Medicine, 1971 - 1972
Maimonides Medical CenterResidency, Internal Medicine, 1969 - 1971
State University of New York Downstate Medical Center College of MedicineClass of 1969
Certifications & Licensure
TX State Medical License 1975 - 2026
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Rheumatology
Awards, Honors, & Recognition
- Master of the American College of Rheumatology ACR, 2009
- Regional Top Doctor Castle Connolly, 2014
- Super Doctor SuperDoctors.com
Clinical Trials
- ETEC Logistics Trial (TREK) Start of enrollment: 2006 May 01
- An Extension Study in Participants With Moderate to Severe Rheumatoid Arthritis Start of enrollment: 2013 Jun 27
- A Study of LY3337641 in Rheumatoid Arthritis Start of enrollment: 2016 Aug 22
- Join now to see all
Publications & Presentations
PubMed
- Association Between Abatacept Exposure Levels and Infection Occurrence in Patients With Rheumatoid Arthritis: Post Hoc Analysis of the AVERT-2 Study.Paul Emery, Roy Fleischmann, Robert Wong, Karissa Lozenski, Yoshiya Tanaka
The Journal of Rheumatology. 2025-03-15 - Long-term safety and efficacy of anti-GM-CSF otilimab in patients with rheumatoid arthritis: long-term extension of three phase 3 randomised trials (contRAst X).Michael E Weinblatt, Peter C Taylor, Iain B McInnes, Tatsuya Atsumi, Vibeke Strand
BMJ Open. 2025-03-05 - Expert consensus statement on the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: 2024 update.Peter Nash, Andreas Kerschbaumer, Victoria Konzett, Daniel Aletaha, Thomas Dörner
Annals of the Rheumatic Diseases. 2025-03-03
Authored Content
- Interpreting the Results of ORAL-Surveillance at ACR 2021November 2021
Press Mentions
‘Pristine’ Safety Profile Sets TYK2i Apart from JAK ‘Baggage’ in Psoriatic Disease, LupusAugust 16th, 2024- AbbVie Presents Long-Term Data Further Supporting the Efficacy and Safety Profile of RINVOQ® (Upadacitinib) Across Multiple Rheumatic Diseases at the EULAR 2023 CongressMay 24th, 2023
- All or Something: Experts Debate LDA vs. Remission as a Target in Rheumatoid ArthritisApril 19th, 2022
- Join now to see all
Professional Memberships
- Member
- Master Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
